Laboratory Corporation of America (LH) Q2 results:
Revenues: $2,768.8M (-3.9%); LabCorp Diagnostics: $1,692.7M (-3.9%); Covance Drug Development: $1,093.7M (-2.9%).
Net Income: $231.6M (+21.6%); EPS: $2.37 (+22.8%); non-GAAP Net Income: $251M (-13.4%); non-GAAP EPS: $2.57 (-12.3%).
CF Ops: $370.7M (+46.2%).
The Company continues to not provide 2020 guidance, citing COVID-19 uncertainties.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.